This company listing is no longer active
Longboard Pharmaceuticals Future Growth
Future criteria checks 0/6
Longboard Pharmaceuticals's earnings are forecast to decline at 7.6% per annum while its annual revenue is expected to grow at 90.6% per year. EPS is expected to grow by 2.5% per annum.
Key information
-7.6%
Earnings growth rate
2.5%
EPS growth rate
| Pharmaceuticals earnings growth | 19.9% |
| Revenue growth rate | 90.6% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 11 Nov 2024 |
Recent future growth updates
Recent updates
Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management
Oct 15My Strategy For Longboard Pharmaceuticals After Its Big Run
Aug 28We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth
Jul 12
Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely
Mar 16Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?
Oct 03We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate
Dec 25Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth
Sep 10We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely
May 28Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans
Feb 11Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation
Oct 27Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business
Jun 12Longboard Pharmaceuticals EPS beats by $0.29
May 10Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2 | -145 | -144 | -153 | 6 |
| 12/31/2025 | N/A | -118 | -99 | -99 | 7 |
| 12/31/2024 | N/A | -86 | -80 | -80 | 7 |
| 9/30/2024 | N/A | -76 | -66 | -66 | N/A |
| 6/30/2024 | N/A | -65 | -59 | -59 | N/A |
| 3/31/2024 | N/A | -58 | -53 | -53 | N/A |
| 12/31/2023 | N/A | -54 | -51 | -51 | N/A |
| 9/30/2023 | N/A | -51 | -50 | -50 | N/A |
| 6/30/2023 | N/A | -49 | -46 | -46 | N/A |
| 3/31/2023 | N/A | -46 | -41 | -41 | N/A |
| 12/31/2022 | N/A | -44 | -38 | -38 | N/A |
| 9/30/2022 | N/A | -41 | -34 | -34 | N/A |
| 6/30/2022 | N/A | -36 | -30 | -30 | N/A |
| 3/31/2022 | N/A | -32 | -27 | -27 | N/A |
| 12/31/2021 | N/A | -28 | -25 | -25 | N/A |
| 9/30/2021 | N/A | -29 | -21 | -20 | N/A |
| 6/30/2021 | N/A | -25 | -15 | -15 | N/A |
| 3/31/2021 | N/A | -20 | -11 | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LBPH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LBPH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LBPH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LBPH is forecast to have no revenue next year.
High Growth Revenue: LBPH is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LBPH's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/02 13:23 |
| End of Day Share Price | 2024/11/29 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Longboard Pharmaceuticals, Inc. is covered by 3 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Neena Bitritto-Garg | Citigroup Inc |
| Yatin Suneja | Guggenheim Securities, LLC |